title: Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.
abstract: Clostridium difficile infection (CDI) is now the leading cause of nosocomial infection. There has been an upsurge of CDI in patients with inflammatory bowel disease (IBD). IBD patients with CDI have increased morbidity and mortality. The establishment, proliferation, and recurrence of CDI in IBD patients form a complex interplay of microbial, environmental, and host-susceptibility factors. Different risk factors have been found predisposing IBD patients to CDI. Vancomycin performs better than metronidazole in treating IBD patients with CDI. Fecal microbiota transplantation continues to be a very effective therapy. New therapeutic modalities such as vaccinations and bile salts are currently being investigated.
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. nfu@interchange.ubc.ca.|, 250-6091 Gilbert Rd., Richmond, BC, V7C 5L9, Canada. nfu@interchange.ubc.ca.
authors.forename: Nancy
authors.initials: N
authors.lastname: Fu
authors.affiliation: Division of Medical Microbiology and Infection Control, Vancouver General Hospital, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Titus
authors.initials: T
authors.lastname: Wong
keywords: Bile salts; Clostridium difficile; Crohn’s disease; Fecal transplant; Inflammatory bowel disease; Metronidazole; Ulcerative colitis; Vancomycin